$ARTL surges after clinical study announcement, with some traders making thousands on the stock

Today’s most trending tickers with positive sentiment (last 24h):

$SPY: 22
$SPX: 11
$DVLT: 8
$VIX: 7
$ASTS: 7
$PANW: 6
$VVOS: 5
$VOO: 4
$NVDA: 4
$ARTL: 4
$AAPL: 4
$ASTC: 4
$USO: 4

$ARTL soars as Artelo Biosciences reports strong gains and announces clinical study expansion into $16B glaucoma market, resulting in a 500% increase in value.

Today’s most trending tickers with positive sentiment (last 24h):

$SPY: 41
$META: 16
$VIX: 14
$ARTL: 13
$RCKT: 11
$SPX: 10
$NXXT: 9
$NVDA: 9
$VVOS: 7
$MSFT: 7
$ASTS: 6
$NBIS: 6
$NFLX: 6
$MU: 5
$VSA: 5
$IPO: 4
$BTC: 4
$DHS: 4

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,188,407 shares of common stock (or pre-funded warrant in lieu thereof) and warrants to

#ARTL Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

www.stocktitan.net/news/ARTL/artelo-bioscie...

📢 Stocks Trending NOW: #META #CRWD #U #RDDT #ONCO #ARTL #VSA #RCKT #BROS #NFLX

Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments Artelo Biosciences (NASDAQ: ARTL) announced expansion of development for ART27.13 as a potential companion therapy to GLP-1 treatments on March 25, 2026. Key actions include a provisional patent filing, initiation of a non‑clinical study, publication of independent research, and supportive CAReS trial observations.The company cites improvements in lean body mass and preclinical reversal of myotoxicity, positioning ART27.13 for muscle preservation alongside rapidly growing GLP-1 use.

#ARTL Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments

www.stocktitan.net/news/ARTL/artelo-bioscie...

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength Artelo Biosciences (NASDAQ: ARTL) expands ART27.13 into the $16.3B glaucoma market via a fully funded investigator-sponsored trial while advancing three clinical programs in oncology support, neuropathic pain, and CNS disorders.Key advantages: positive Phase 2 signals, MHRA guidance for ART12.11, FABP inhibitor Phase 1 safety, European patent protection to 2041, and a $25M equity facility.

#ARTL Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength

www.stocktitan.net/news/ARTL/artelo-bioscie...

Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study Artelo Biosciences (NASDAQ: ARTL) is expanding into glaucoma with a fully funded investigator-sponsored trial evaluating ART27.13, with first patient enrollment expected in Q2 2026. The move diversifies the pipeline without shareholder dilution and leverages a peripherally selective CB2-targeting mechanism. Key milestones include ongoing Phase 2 CAReS data and a European patent extending protection through December 2041. The global glaucoma market is projected to reach USD 16.31 billion by 2033, underscoring the commercial opportunity while noting typical early-stage clinical and regulatory risks.

#ARTL Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study

www.stocktitan.net/news/ARTL/vanderbilt-rep...

Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients Artelo Biosciences (Nasdaq: ARTL) entered a definitive investigator-initiated study agreement with Belfast Health and Social Care Trust to evaluate oral ART27.13 in glaucoma and ocular hypertension. The pilot, randomized cross-over study is funded by Glaucoma UK and HSC R&D, has ethics and MHRA approval, and expects first patient enrollment in Q2 2026. Artelo will supply ART27.13 capsules; the program tests a peripherally selective cannabinoid approach to lower intraocular pressure while avoiding central nervous system effects.

#ARTL Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients

www.stocktitan.net/news/ARTL/artelo-announc...

Artelo Biosciences Announces Reverse Stock Split Artelo Biosciences (Nasdaq: ARTL) announced a 3-for-1 reverse stock split approved by the board on February 27, 2026. The split will combine every three outstanding shares into one and will be effective for trading on a split-adjusted basis at the open on March 10, 2026.The company said the Board adopted the 3-for-1 ratio to increase the per-share price to improve marketability and liquidity. The new CUSIP after the reverse split will be 04301G706, and there will be approximately 708,258 shares issued and outstanding immediately after the split. All outstanding warrants and derivatives will automatically adjust per their terms.

#ARTL Artelo Biosciences Announces Reverse Stock Split

www.stocktitan.net/news/ARTL/artelo-bioscie...

Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate Artelo Biosciences (Nasdaq: ARTL) commented on the Dec 23, 2025 White House Executive Order creating a Medicare pilot for cannabidiol (CBD) reimbursement and structured data collection.Artelo said the initiative could improve access and generate data to inform research and potential Medicaid expansion. The company highlighted ART12.11, its patented CBD–tetramethylpyrazine cocrystal, stating superior oral bioavailability, more consistent pharmacokinetics, and enhanced efficacy signals in preclinical anxiety and depression models. Artelo reported the Drug Enforcement Agency indicated ART12.11 would not be considered a controlled substance and said it is prepared to complete final steps to advance ART12.11 into human clinical trials.

#ARTL Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate

www.stocktitan.net/news/ARTL/artelo-bioscie...

A digital illustration of a “female character” from Xenoblade Chronicles X. She is wearing a festive elf outfit and sitting on the edge of Santa’s sleigh with her legs crossed. Behind her is Santa’s sack of presents, with a hidden Tatsu wearing a Santa hat. The background is a starry night sky with a massive moon designed to spotlight the main subjects in this piece.

4 years ago today, I drew this festive piece!

It got slept on back then which was such a shame because I love how it came out. It aged well too, apart from the hair being rather stripey. Also it came with a cute pun for a title which I can’t say for spoiler reasons 😭
#artl

Leading Indicators, Wednesday December 3, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Wed Dec 3rd - #ARTL #DEVS #IMRN #LOT #WOK #VS #SONN #POLE #OMDA #IPWR #HCMA #CLNN #BWIN #ACHC #ADCT - More: crystalequityresearch.com/leading-indi... - #smallcap

Leading Indicators, Monday December 1, 2025 – Crystal Equity Research

Small-cap stocks with strong volume gains, Mon Dec 1st - #WBUY #SUNS #JFBR #HKIT #GLBS #FLYE #ARTL #WHLR #STTK #QTTR #VEEE #KALA #IRBT #FTEL #DRCT #CNCK #BLTE #LEG #CYH #BALY - More: crystalequityresearch.com/leading-indi... - #smallcap

Trade Alerts, Wednesday November 26, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading, Wed Nov 26th - #MURA #CIFRW #ARTL #SNT #MBRX #KXIN #GORV #ALAR #PD - More: crystalequityresearch.com/trade-alerts... - #smallcap

#ARTL Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/ARTL/artelo-bioscie...

Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people

#ARTL Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

www.stocktitan.net/news/ARTL/artelo-bioscie...

Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer Artelo Biosciences (Nasdaq: ARTL) named Mark Spring, CPA, as Chief Financial Officer, effective November 1, 2025.Mr. Spring has served as a financial consultant to Artelo since December 2024 and brings 30 years of life‑sciences financial leadership, including interim CFO and CFO roles at multiple commercial and development‑stage companies and significant M&A and licensing experience. The appointment is presented as strengthening financial leadership as Artelo advances its clinical pipeline and corporate growth initiatives.

#ARTL Artelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer

www.stocktitan.net/news/ARTL/artelo-bioscie...

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit Artelo Biosciences (Nasdaq: ARTL) will present expanded clinical data on ART26.12 and interim Phase 2 data on ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit on October 15–16, 2025 in Boston.Key findings: ART26.12 single ascending dose study showed safety at single doses up to 1050 mg, predictable linear plasma exposure, and potential dosing flexibility in fed or fasted states. ART27.13 Phase 2 interim data in cancer anorexia showed treated patients (up to 1300 µg/day on average) gained >b>6% body weight versus placebo patients who lost an additional 5%, with a similar tolerability profile to earlier stages to date.

#ARTL Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

www.stocktitan.net/news/ARTL/artelo-bioscie...

$2 Million Capital Raise: Artelo Biosciences Prices Public Offering for Cancer Drug Development Clinical-stage pharma Artelo Biosciences prices offering of 441,210 shares at $4.40/share plus warrants. Expected to close Oct 1, with R.F. Lafferty as book-runner.

#ARTL Artelo Biosciences Announces Pricing of $2.0 Million Public Offering

www.stocktitan.net/news/ARTL/artelo-bioscie...

Nasdaq-Listed Biotech Artelo Biosciences Announces New Public Stock Offering for Cancer Research Artelo Biosciences (ARTL) commences underwritten public offering of common stock and pre-funded warrants. R.F. Lafferty & Co. to serve as sole book-running manager.

#ARTL Artelo Biosciences Announces Proposed Underwritten Public Offering

www.stocktitan.net/news/ARTL/artelo-bioscie...

Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference Artelo Biosciences (Nasdaq: ARTL) presented positive interim Phase 2 CAReS data for ART27.13 at the 2025 Cancer Cachexia Society Conference. The drug, targeting cancer anorexia-cachexia syndrome (CACS), demonstrated significant benefits in key metrics:Patients receiving the highest dose (1300 µg) achieved an average +6% weight gain over 12 weeks, while placebo patients lost ~5%. The treatment showed improvements in lean body mass and increased daily activity levels, confirmed through digital wearable data. The drug maintained a favorable safety profile with mostly mild to moderate adverse events and no serious drug-related incidents.Professor Barry Laird from Oslo University Hospital presented the data, while the company engaged in partnering discussions to advance the program's commercial potential.

#ARTL Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference

www.stocktitan.net/news/ARTL/artelo-bioscie...

#aiart #blueskyart #artl

Leading Indicators, Thursday September 4, 2025 – Crystal Equity Research

Small-cap stocks gapping down in trading, Thu Sept 4th - #ARTL #SDST #PPBT #NEON #CRMT #AEMD #DOLE #DAVA #CAL #AAMI - More: crystalequityresearch.com/leading-indi... - #smallcap

$3 Million Capital Raise: Clinical-Stage Biotech Artelo Prices Public Offering for Cancer & Pain Research Clinical-stage pharma Artelo Biosciences prices offering of 640,924 shares at $4.40 and 40,894 pre-funded warrants. R.F. Lafferty leads $3M raise for cancer and pain research programs.

#ARTL Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

www.stocktitan.net/news/ARTL/artelo-bioscie...

Clinical-Stage Pharma Artelo Biosciences Launches New Public Stock Offering via R.F. Lafferty Artelo Biosciences (ARTL) initiates underwritten public offering of common stock and pre-funded warrants. R.F. Lafferty & Co. to serve as sole book-running manager.

#ARTL Artelo Biosciences Announces Proposed Underwritten Public Offering

www.stocktitan.net/news/ARTL/artelo-bioscie...

Cancer Wasting Treatment Breakthrough: Artelo's ART27.13 Shows Promise in Phase 2 Trial for 80% of Cancer Patients Artelo's ART27.13 demonstrates improvements in weight, lean body mass, and activity in Phase 2 CAReS trial for cancer cachexia. Company pursuing partnership for Phase 3 development.

#ARTL Artelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results

www.stocktitan.net/news/ARTL/artelo-bioscie...

Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS) Artelo Biosciences (Nasdaq: ARTL) announced encouraging interim results from its Phase 2 Cancer Appetite Recovery Study (CAReS) trial for ART27.13, a treatment for cancer anorexia-cachexia syndrome (CACS). The study showed significant positive outcomes, with patients receiving the 1300 microgram dose achieving a +6.38% mean weight gain after 12 weeks, compared to -5.42% loss in placebo group.Key highlights include a +4.23% increase in lean body mass at one month for treated patients, while placebo patients lost -3.15%. The drug demonstrated a favorable safety profile with mostly mild to moderate adverse events. The positive results are accelerating Artelo's partnering discussions with pharmaceutical companies for ART27.13, which targets CACS, a condition affecting up to 80% of cancer patients with no current FDA-approved treatment.

#ARTL Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)

www.stocktitan.net/news/ARTL/artelo-bioscie...

Charts of the Day - small-cap stocks forming bullish engulfing candlestick signal, Mon Aug 25th - #ARTL #RAY - More: crystalequityresearch.com/charts-of-th... - #smallcap